HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JF-10-81

camptothecin conjugated to the N-terminal of a somatostatin analog directly via a carbamate group and a basic N-terminal linking motif, D-Lys-D-Tyr-Lys-D-Tyr-D-Lys

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Coy, David H: 4 articles (01/2011 - 07/2004)
2.	Fuselier, Joseph A: 3 articles (01/2008 - 07/2004)
3.	Sun, Li-Chun: 2 articles (01/2011 - 01/2008)
4.	Luo, Jing: 1 article (01/2008)
5.	Mackey, L Vienna: 1 article (01/2008)
6.	Bezerra, Yanno: 1 article (04/2005)
7.	Drouant, George: 1 article (04/2005)
8.	Oner, Hakan: 1 article (04/2005)
9.	Peyman, Gholam A: 1 article (04/2005)
10.	Sun, Lichun: 1 article (07/2004)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2008 - "Also, JF-10-81 was used to treat highly invasive PC-3 tumors where s.c. " 07/01/2004 - "Both cytotoxic conjugates significantly inhibited growth of SSTR2-specific pancreatic and SCLC tumors, but JF-10-81 did not significantly affect PC-3 tumor growth. " 07/01/2004 - "CA20948 tumors, known to overexpress SSTR2 and grown in Lewis rats, were treated, respectively, with nontoxic 400 nmol/kg intraperitoneal (i.p.) doses of JF-10-71 or JF-10-81. " 07/01/2004 - "JF-10-71 and JF-10-81 also were examined for their inhibitory effects on the growth of this and several other tumors transplanted into rats (CA20948) or nude mice. " 01/01/2011 - "For instance, the CPT-SST conjugate JF-10-81, in which CPT is coupled to the N-terminus of a SSTR2-specific SST analog (JF-07-69), had wide ranging anti-tumor and anti-angiogenic ability. "
2.	Neuroblastoma 01/01/2008 - "JF-10-81 was found to significantly inhibit growth of these SSTR-positive tumors, resulting in 87% tumor reduction in neuroblastoma IMR32 and 97% in leukemia MOLT-4 bearing animals, even inducing regression of CFPAC-1 tumors. " 01/01/2008 - "JF-10-81 was tested for its inhibitory activity against the growth of human tumors which included neuroblastoma (IMR32), pancreatic cancer (CFPAC-1), leukemia (MOLT-4), pancreatic carcinoid (BON) and prostate cancer (PC-3). " 07/01/2004 - "Two CPT-SSA conjugates, JF-10-71 and JF-10-81, containing a chemically adjustable release-rate carbamate linker, have been reported previously by us to potently inhibit growth of human neuroblastoma IMR32 cells overexpressing somatostatin receptor type II (SSTR2) but are stable under buffer incubation conditions or in rat plasma. "
3.	Choroidal Neovascularization 04/01/2005 - "Part 2: Conjugate JF-10-81 at a concentration of 10(-5)M administered intravitreally 1 to 3 weeks after laser demonstrated statistically significant efficacy in the treatment of choroidal neovascularization."
4.	Prostatic Neoplasms (Prostate Cancer) 01/01/2008 - "JF-10-81 was tested for its inhibitory activity against the growth of human tumors which included neuroblastoma (IMR32), pancreatic cancer (CFPAC-1), leukemia (MOLT-4), pancreatic carcinoid (BON) and prostate cancer (PC-3). "
5.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2008 - "JF-10-81 was tested for its inhibitory activity against the growth of human tumors which included neuroblastoma (IMR32), pancreatic cancer (CFPAC-1), leukemia (MOLT-4), pancreatic carcinoid (BON) and prostate cancer (PC-3). "

Related Drugs and Biologics

1.	2- cyclohexylidenhydrazo- 4- phenyl- thiazole
2.	Somatostatin Receptors (Somatostatin Receptor)
3.	Carbamates
4.	Buffers

Related Therapies and Procedures

1.	Lasers (Laser)